Investment analysts at Stifel Nicolaus assumed coverage on shares of Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) in a research note issued on Tuesday, Briefing.com reports. The firm set a “buy” rating and a $35.00 price target on the stock.
Rapport Therapeutics Price Performance
Read More
- Five stocks we like better than Rapport Therapeutics
- The 3 Best Retail Stocks to Shop for in August
- Snowflake Stock Rebounds, Flies Higher on AI Spending
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Complete Solaria, Senti, and POET: 3 High Volume Penny Stocks
- What Investors Need to Know About Upcoming IPOs
- Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
